Добірка наукової літератури з теми "M. tuberculosis - Rifampicin"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "M. tuberculosis - Rifampicin".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "M. tuberculosis - Rifampicin"
Danlami, Mohammed Bashar, Basiru Aliyu, and Grace Samuel. "INCIDENCE OF RIFAMPICIN-RESISTANCE PRESUMPTIVE M. TUBERCULOSIS CASES AMONG OUTPATIENTS IN KEBBI STATE, NIGERIA." African Journal of Infectious Diseases 15, no. 1 (December 15, 2020): 47–52. http://dx.doi.org/10.21010/ajid.v15i1.6.
Повний текст джерелаde la Iglesia, Agustina I., Emma J. Stella, and Héctor R. Morbidoni. "Comparison of the Performances of Two In-House Rapid Methods for Antitubercular Drug Susceptibility Testing." Antimicrobial Agents and Chemotherapy 53, no. 2 (November 17, 2008): 808–10. http://dx.doi.org/10.1128/aac.00960-08.
Повний текст джерелаАХМЕТОВА, А. Ж., Ж. М. АБИЛОВА, Г. Н. ЖАРЫЛҚАСЫН, А. Р. АКИЛЬЖАНОВА та У. А. КОЖАМКУЛОВ. "ҚАЗАҚСТАНДА ТАРАЛҒАН РИФАМПИЦИН-ТӨЗІМДІ M. TUBERCULOSIS КЛИНИКАЛЫҚ ИЗОЛЯТТАРЫНЫҢ ГЕНЕТИКАЛЫҚ СИПАТТАМАСЫ". Vestnik, № 1(64) (14 квітня 2023): 53–65. http://dx.doi.org/10.53065/j5985-7576-8270-u.
Повний текст джерелаGautam, Praveen B., Ashwini Mishra, and Santosh Kumar. "Prevalence of rifampicin resistant mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients in eastern Uttar Pradesh: a cross sectional study." International Journal Of Community Medicine And Public Health 5, no. 6 (May 22, 2018): 2271. http://dx.doi.org/10.18203/2394-6040.ijcmph20182039.
Повний текст джерелаSanzhakov, M. A., O. M. Ipatova, T. I. Torkhovskaya, E. G. Tikhonova, N. V. Medvedeva, T. S. Zakharova, and V. N. Prozorovskiy. "Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate." Biomeditsinskaya Khimiya 64, no. 6 (2018): 505–10. http://dx.doi.org/10.18097/pbmc20186406505.
Повний текст джерелаNotopuro, P. B., J. Nugraha, and H. Notopuro. "DETEKSI MOLEKUL MUTASI GEN rpoB MYCOBACTERIUM TUBERCULO SIS PADA DAHAK DENGAN POL YME RASE CHAIN REACTION DAN SINGLE STRAND CONFORMATION POLYMORPHISM." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 16, no. 2 (March 16, 2018): 81. http://dx.doi.org/10.24293/ijcpml.v16i2.973.
Повний текст джерелаN. Djide, Nana Juniarti, M. Natsir Djide, Muhammad Nur Amir, and Sartini Sartini. "Aktivitas Antibakteri Ekstrak Kelopak Bunga Rosella Terenkapsulasi Maltodekstrin dan Sinergitasnya dengan Isoniazida dan Rifampisin Terhadap Mycobacterium tuberculosis H37rv." Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) 5, no. 2 (October 15, 2019): 117. http://dx.doi.org/10.22487/j24428744.0.v0.i0.12946.
Повний текст джерелаN. Djide, Nana Juniarti, M. Natsir Djide, Muhammad Nur Amir, and Sartini Sartini. "Aktivitas Antibakteri Ekstrak Kelopak Bunga Rosella Terenkapsulasi Maltodekstrin dan Sinergitasnya dengan Isoniazida dan Rifampisin Terhadap Mycobacterium tuberculosis H37rv." Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) 5, no. 2 (October 15, 2019): 117–23. http://dx.doi.org/10.22487/j24428744.2019.v5.i2.12946.
Повний текст джерелаMohiuddin, Md, and J. Ashraful Haq. "First Line Anti-Tubercular Drug Resistance Pattern of Mycobacterium Tuberculosis Isolated From Specialized Hospitals of Dhaka City." Ibrahim Medical College Journal 8, no. 2 (February 4, 2016): 41–46. http://dx.doi.org/10.3329/imcj.v8i2.26677.
Повний текст джерелаKashyap, Bineeta, Nisha Goyal, Puneeta Hyanki, NP Singh, and Ashwani Khanna. "Cartridge-based nucleic acid amplification test: a novel rapid diagnostic tool to study the burden of tuberculosis from a tertiary care hospital." Tropical Doctor 49, no. 4 (July 10, 2019): 274–81. http://dx.doi.org/10.1177/0049475519859958.
Повний текст джерелаДисертації з теми "M. tuberculosis - Rifampicin"
Bhuju, Sabin [Verfasser], and M. [Akademischer Betreuer] Singh. "Development of novel drug screening assays and molecular characterization of rifampicin and pyrazinamide resistance in Mycobacterium tuberculosis / Sabin Bhuju ; Betreuer: M. Singh." Braunschweig : Technische Universität Braunschweig, 2008. http://d-nb.info/1175828823/34.
Повний текст джерелаPaiva, Marcelo Vitor de. "Otimiza??o e valida??o de m?todos anal?ticos para a determina??o simult?nea de tuberculost?ticos (4-FDC) por CLAE/DAD e CLUE/ DAD." Universidade Federal do Rio Grande do Norte, 2013. http://repositorio.ufrn.br:8080/jspui/handle/123456789/13477.
Повний текст джерелаTuberculosis is a serious disease, but curable in practically 100% of new cases, since complied the principles of modern chemotherapy. Isoniazid (ISN), Rifampicin (RIF), Pyrazinamide (PYR) and Chloride Ethambutol (ETA) are considered first line drugs in the treatment of tuberculosis, by combining the highest level of efficiency with acceptable degree of toxicity. Concerning USP 33 - NF28 (2010) the chromatography analysis to 3 of 4 drugs (ISN, PYR and RIF) last in average 15 minutes and 10 minutes more to obtain the 4th drug (ETA) using a column and mobile phase mixture different, becoming its industrial application unfavorable. Thus, many studies have being carried out to minimize this problem. An alternative would use the UFLC, which is based with the same principles of HPLC, however it uses stationary phases with particles smaller than 2 ?m. Therefore, this study goals to develop and validate new analytical methods to determine simultaneously the drugs by HPLC/DAD and UFLC/DAD. For this, a analytical screening was carried out, which verified that is necessary a gradient of mobile phase system A (acetate buffer:methanol 94:6 v/v) and B (acetate buffer:acetonitrile 55:45 v/v). Furthermore, to the development and optimization of the method in HPLC and UFLC, with achievement of the values of system suitability into the criteria limits required for both techniques, the validations have began. Standard solutions and tablets test solutions were prepared and injected into HPLC and UFLC, containing 0.008 mg/mL ISN, 0.043 mg/mL PYR, 0.030 mg.mL-1 ETA and 0.016 mg/mL RIF. The validation of analytical methods for HPLC and UFLC was carried out with the determination of specificity/selectivity, analytical curve, linearity, precision, limits of detection and quantification, accuracy and robustness. The methods were adequate for determination of 4 drugs separately without interfered with the others. Precise, due to the fact of the methods demonstrated since with the days variation, besides the repeatability, the values were into the level required by the regular agency. Linear (R> 0,99), once the methods were capable to demonstrate results directly proportional to the concentration of the analyte sample, within of specified range. Accurate, once the methods were capable to present values of variation coefficient and recovery percentage into the required limits (98 to 102%). The methods showed LOD and LOQ very low showing the high sensitivity of the methods for the four drugs. The robustness of the methods were evaluate, facing the temperature and flow changes, where they showed robustness just with the preview conditions established of temperature and flow, abrupt changes may influence with the results of methods
A tuberculose ? uma doen?a grave, por?m cur?vel em praticamente 100% dos casos novos, desde que obedecidos os princ?pios da moderna quimioterapia. S?o considerados f?rmacos de 1? linha no tratamento ? tuberculose: isoniazida, pirazinamida, etambutol e rifampicina. De acordo com USP 33 - NF28 (2010) as an?lises cromatogr?ficas para 3 dos 4 f?rmacos (isoniazida, pirazinamida e rifampicina) duram em m?dia 15 minutos e mais 10 minutos para a obten??o do 4? f?rmaco (etambutol) utilizando outra coluna, com outra mistura de fase m?vel, tornando esta aplica??o na pr?tica industrial desfavor?vel. Uma das alternativas ? utilizar o CLUE, o qual baseia-se nos mesmos princ?pios da CLAE, por?m utiliza fases estacion?rias com part?culas menores que 2 ?m. Dessa forma pretende-se com o presente estudo desenvolver e validar novos m?todos anal?ticos para determina??o simult?nea de tuberculost?ticos por CLAE/DAD e CLUE/DAD. Para isto, foi realizado um screening anal?tico, o qual verificou que ? necess?rio um gradiente de sistema de fase m?vel A (tamp?o acetato:metanol 94:6 v/v) e B (tamp?o acetato:acetonitrila 55:45 v/v). Posteriormente, ao desenvolvimento e otimiza??o do m?todo em CLAE e CLUE com a obten??o dos valores de adequabilidade do sistema dentro dos limites de aceita??es vigente para ambos as t?cnicas, as valida??es deram-se in?cio. Solu??es padr?es e solu??es testes dos comprimidos foram preparadas e injetadas no CLAE e CLUE, contendo isoniazida, pirazinamida, etambutol e rifampicina nas concentra??es de 0,008, 0,043, 0,030 e 0,016 mg.mL-1, respectivamente. A valida??o dos m?todos anal?ticos foram realizadas para: especificidade / seletividade, intervalos da curva anal?tica, linearidade, limite de detec??o, limite de quantifica??o, exatid?o, precis?o (repetibilidade, precis?o intermedi?ria) e robustez. Os m?todos foram adequados para determina??o dos 4 f?rmacos separadamente sem interfer?ncia nos demais. Precisos, devido ao fato de que os m?todos demonstraram que mesmo com varia??o de dias, al?m da repetibilidade, os valores ficaram dentro da faixa preconizada na legisla??o vigente. Lineares (R > 0,99), ou seja, os m?todos foram capazes de demonstrar que os resultados obtidos eram diretamente proporcionais ? concentra??o do analito na amostra, dentro de um intervalo especificado. Exatos, uma vez que os m?todos foram capazes de apresentar valores de coeficiente de varia??o e porcentagem de recupera??o dentro dos limites exigidos (98 a 102%). Os m?todos mostraram LD e LQ com n?veis baixos demonstrando que os m?todos possuem elevada sensibilidade aos quarto f?rmacos. A robustez foi avaliada frente ?s altera??es de temperatura e fluxo, onde os m?todos demonstraram-se robustos apenas nas condi??es previamente estabelecidas de temperatura e fluxo, altera??es bruscas podem acarretar influ?ncia nos resultados dos m?todos
Veldsman, Chrisna. "The prevalence of isoniazid and rifampicin resistance of Mycobacterium tuberculosis." Diss., 2010. http://hdl.handle.net/2263/24638.
Повний текст джерелаDissertation (MSc)--University of Pretoria, 2010.
Medical Microbiology
unrestricted
Sebastian, Jees. "Response of Mycobacterium Tuberculosis to Rifampicin - A Cellular, Molecular, and Ultrastructural Study." Thesis, 2016. http://etd.iisc.ac.in/handle/2005/3116.
Повний текст джерелаSebastian, Jees. "Response of Mycobacterium Tuberculosis to Rifampicin - A Cellular, Molecular, and Ultrastructural Study." Thesis, 2016. http://hdl.handle.net/2005/3116.
Повний текст джерелаSharmada, S. "Cellular and Molecular Features of the Response of Mycobacterium smegmatis to Rifampicin and Moxifloxacin Upon Prolonged Exposure." Thesis, 2017. http://etd.iisc.ac.in/handle/2005/4168.
Повний текст джерелаLiu, Shu-feng, and 劉淑鳳. "The epidemiologic comparison of M. avium complex with M. tuberculosis complex and genetic analysis of Rifampicin resistance for M. avium complex of the Infection Disease Hospital in Kaohsiung and Pingtung areas." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/93792242147031238964.
Повний текст джерела嘉南藥理科技大學
生物科技系暨研究所
98
Abstract Mycobacterium avium complex (MAC) belongs to a group of slow growing mycobacteria. Many studies showed that chronic pulmonary disease is most commonly manifestated by a non-tuberculous mycobacteria (NTM) infection. MAC, M. kansasii, and M. abscessus, in order of frequency, are the most common pathogens of NTM lung disease. We found the patients with NTM lung disease were more than those with pulmonary tuberculosis between July, 2007 and December, 2008 and MAC was the most common pathogen of NTM lung disease. A case-control was conducted study and 30 patients with a positive sputum culture for MAC as the case group and 30 patients with a positive sputum culture for M. tuberculosis as the control group were enrolled. The two groups were matched with sex, residential areas, and patient services (outpatients or inpatients). Several variables as predictors of risk factors were used to evaluate acquiring NTM lung disease, including age, height, weight﹐BMI﹐DM, smoking, upper lung fields﹐lower lung fields, and pulmonary cavities. We also compared the gene sequence by sequencing to identify the Rifampicin resistance gene of MAC. Involvement of lower lung fields were more common in MAC lung disease (McNemar test, p <0.05), while the pulmonary cavities were more common in pulmonary tuberculosis (Logistic regression, p <0.05). Finally, EMBOSS were used for the database of M.avium AF060366 and sequence analysis. Three strains with a point mutation (Glycine→Aspartic acid) in the nucleotide sequence 433 was noted. Twenty-six strains (87%) presented the phenotype of Rifampicin resistance, while 4 strains were sensitive to Rifampicin (13%). However, genotypes of Rifampicin resistance were noted for only 11% of the strains. It implies that a new criteria for clinical susceptibility test should be established to provide a more convenient, cheap and accurate method for the in-vitro susceptibility test.
Частини книг з теми "M. tuberculosis - Rifampicin"
Boakye-Appiah, Justice, Belinda Hall, Rajko Reljic, and Rachel E. Simmonds. "Current Progress and Prospects for a Buruli Ulcer Vaccine." In Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 71–95. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_5.
Повний текст джерелаDian Novita, Bernadette, Ari Christy Mulyono, and Ferdinand Erwin. "Metformin for Tuberculosis Infection." In Metformin - Pharmacology and Drug Interactions. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99794.
Повний текст джерелаТези доповідей конференцій з теми "M. tuberculosis - Rifampicin"
Pompermaier, Carolina, Mateus Xavier Schenato, Tales Antunes Franzini, Fábio Biguelini Duarte, and Guilherme Roloff Cardoso. "TUBERCULOUS LYMPHADENITIS: A LITERATURE REVIEW." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1080.
Повний текст джерела